8-K: Harmony Biosciences Unveils Promising Preclinical Data for BP1.15205, Advancing Narcolepsy Treatment Pipeline

Harmony Biosciences announced strong preclinical results for its investigational OX2R agonist, BP1.15205, showing significant wake-promoting and cataplexy-suppressing effects, with a first-in-human study planned for late 2025.

Summary

• Harmony Biosciences presented new preclinical pharmacological effect data for BP1.15205, an investigational orexin 2 receptor (OX2R) agonist.
• BP1.15205 demonstrated significant wake-promoting and cataplexy-suppressing effects in a standard transgenic mouse model of narcolepsy type 1.
• The data was presented at the 39th Annual Meeting of the Associated Professional Sleep Societies (APSS) SLEEP on June 11, 2025.
• BP1.15205 is described as a highly potent, selective OX2R agonist with no expected off-target effects and >600-fold selectivity over human OX1R.
• It is orally bioavailable and has the potential for once-daily dosing.
• A 3-month GLP toxicity study in two species revealed no concerning adverse events at doses up to 300 mg/kg/day, supporting a favorable safety and tolerability profile.
• An Investigational Medicinal Product Dossier (IMPD) application with the European Medicines Agency (EMA) is being completed.
• A first-in-human study is planned to begin in the second half of 2025, with topline data anticipated in 2026.
• An Investigational New Drug (IND) application for BP1.15205 will be filed with the U.S. Food and Drug Administration (FDA).

Sentiment

Score: 9

Explanation: The document presents overwhelmingly positive preclinical data for a key pipeline asset, BP1.15205, highlighting its potency, selectivity, and favorable safety profile. The clear path to first-in-human studies and regulatory filings indicates strong progress and strategic expansion, with no apparent negative news or delays.

Positives

• BP1.15205 demonstrated significant wake-promoting and cataplexy-suppressing effects in a standard transgenic mouse model of narcolepsy type 1.
• It is a highly potent agonist at OX2R receptors with an EC50 = 0.015 nM.
• BP1.15205 showed high selectivity for human OX2R receptors (>600-fold selectivity over human OX1R receptors) with no off-target effects expected.
• The compound is orally bioavailable and has the potential for once-daily dosing.
• A 3-month GLP toxicity study showed no concerning adverse events or biochemical changes at doses up to 300 mg/kg/day, indicating a favorable safety and tolerability profile.
• The preclinical findings support dosing flexibility to potentially treat all three central disorders of hypersomnolence at low doses, which could offer an optimized benefit/risk profile.
• Advancement of a potentially "best-in-class" OX2R program expands the company's sleep-wake franchise.

Risks

• Commercialization efforts and strategy for WAKIX.
• Rate and degree of market acceptance and clinical utility of pitolisant in additional indications, if approved, and any other product candidates (including ZYN002 and EPX-100).
• Research and development plans, including exploring therapeutic potential of pitolisant in additional indications.
• Ongoing and planned clinical trials.
• Ability to expand the scope of license agreements with Bioprojet Socit Civile de Recherche (Bioprojet).
• Availability of favorable insurance coverage and reimbursement for WAKIX.
• Timing of, and ability to obtain, regulatory approvals for pitolisant for other indications as well as any other product candidates.
• Estimates regarding expenses, future revenue, capital requirements, and additional financing needs.
• Ability to identify, acquire, and integrate additional products or product candidates with significant commercial potential.
• Significant competition in the industry.
• Intellectual property position.
• Loss or retirement of key members of management.
• Failure to successfully execute growth strategy, including any delays in planned future growth.
• Failure to maintain effective internal controls.
• Impact of government laws and regulations.
• Volatility and fluctuations in the price of common stock.
• Significant costs and required management time as a result of operating as a public company.
• Price of Harmony's common stock may be volatile and fluctuate substantially.
• Statements related to intended share repurchases and repurchase timeframe.
• Macroeconomic effects and changes in market conditions, including tariffs, inflation, and risk of recession.

Future Outlook

Harmony Biosciences plans to complete an Investigational Medicinal Product Dossier (IMPD) application with the European Medicines Agency (EMA) for BP1.15205. A first-in-human study is scheduled to commence in the second half of 2025, with topline data expected in 2026. Additionally, an Investigational New Drug (IND) application for BP1.15205 will be filed with the U.S. Food and Drug Administration (FDA). The company aims to advance this potentially best-in-class OX2R program to expand its sleep-wake franchise and bring a novel treatment to market for narcolepsy and other central disorders of hypersomnolence.

Management Comments

• "We are encouraged by the robust preclinical data being presented at SLEEP, highlighting BP1.15205 as a potentially best-in-class OX2R agonist." Kumar Budur, MD, MS, Chief Medical and Scientific Officer.
• "BP1.15205 is a new and unique chemical scaffold optimized for high potency that demonstrated statistically significant wake-promoting effects at very low doses administered orally in the standard transgenic mouse model." Kumar Budur, MD, MS, Chief Medical and Scientific Officer.
• "These findings are supportive of dosing flexibility to potentially treat all three central disorders of hypersomnolence at low doses, which could offer an optimized benefit / risk profile." Kumar Budur, MD, MS, Chief Medical and Scientific Officer.
• "The 3-month GLP toxicity study in two species revealed no concerning adverse events and supports a favorable safety and tolerability profile." Kumar Budur, MD, MS, Chief Medical and Scientific Officer.
• "We are very excited to advance our potentially best-in-class OX2R program and support the strategic expansion of our sleep-wake franchise. We are dedicated to investigating this potential new solution further with the hope of bringing a novel treatment to market that can help even more people with narcolepsy and other central disorders of hypersomnolence." Kumar Budur, MD, MS, Chief Medical and Scientific Officer.

Industry Context

Narcolepsy is a rare, chronic neurological disease affecting approximately 170,000 Americans, characterized by excessive daytime sleepiness (EDS) and cataplexy, often caused by the loss of hypocretin/orexin. OX2R agonists like BP1.15205 aim to restore sleep-wake stability by targeting the orexin system, representing a key therapeutic approach for this unmet medical need. Harmony Biosciences' focus on this area aligns with the broader industry trend of developing targeted therapies for rare neurological disorders.

Comparison to Industry Standards

• The document states BP1.15205 is a "potentially best-in-class" OX2R agonist and "differentiated" from other OX2R agonist drug candidates.
• It highlights "high potency" (EC50 = 0.015 nM) and ">600-fold selectivity over human OX1R," which are strong indicators of a favorable profile compared to general industry benchmarks for drug candidates.
• The favorable 3-month GLP toxicity study results (no concerning adverse events at doses up to 300 mg/kg/day) also suggest a strong safety profile in preclinical stages, which is a critical benchmark for advancing drug candidates.
• No specific comparable companies, projects, or their results are explicitly named for direct comparison.

Stakeholder Impact

• Shareholders: Positive impact due to promising preclinical data for a new drug candidate, potentially expanding the company's pipeline and future revenue streams.
• Patients (with narcolepsy and other central disorders of hypersomnolence): Potential for a novel, effective, and well-tolerated treatment option in the future.
• Employees: Positive outlook due to pipeline advancement and strategic growth.

Next Steps

• Complete Investigational Medicinal Product Dossier (IMPD) application with the European Medicines Agency (EMA) for BP1.15205.
• Begin a first-in-human study for BP1.15205 in the second half of 2025.
• File an Investigational New Drug (IND) application for BP1.15205 with the U.S. Food and Drug Administration (FDA).
• Anticipate topline data from the first-in-human study in 2026.
• Present the preclinical data at the 39th Annual Meeting of the Associated Professional Sleep Societies (APSS) SLEEP on June 11, 2025.

Key Dates

Recommendation

Keywords

Harmony Biosciences, HRMY, BP1.15205, narcolepsy, orexin 2 receptor agonist, OX2R, sleep disorders, hypersomnolence, preclinical data, drug development, pharmaceutical, FDA, EMA, clinical trials